Showing results (281-290 of 672) with videos related to
Sort By:
Pageof 68
Metabolic Brain Disease|March 1, 1989
Biochemical events in spontaneous seizures in the Mongolian gerbilR Wolf-Dieter, G Heuschneider, G Sperk, et al.Biogerontology|November 16, 2001
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?S Dukic-Stefanovic, R Schinzel, P Riederer, et al.Journal of Neural Transmission|January 1, 1975
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, DeprenilW Birkmayer, P Riederer, M B Youdim, et al.Journal of Neural Transmission. Supplementum|January 1, 1995
Interaction of neuroprotective substances with human brain superoxide dismutase. An in vitro studyW Gsell, N Reichert, M B Youdim, et al.Neurotoxicology|December 31, 2003
Monoamine oxidase inhibition and CNS immunodeficiency infectionE Koutsilieri, C Scheller, V ter Meulen, et al.Arzneimittel-Forschung|February 1, 1992
Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophreniaP Riederer, K W Lange, J Kornhuber, et al.Brain Research|August 5, 1998
Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's diseaseG Münch, A M Cunningham, P Riederer, et al.European Journal of Pharmacology|December 12, 1991
MPTP mechanisms of neurotoxicity and their implications for Parkinson's diseaseM Gerlach, P Riederer, H Przuntek, et al.Acta Neuropathologica|December 5, 1997
Low prevalence of apolipoprotein E epsilon 4 allele in the neurofibrillary tangle predominant form of senile dementiaC Bancher, R Egensperger, S Kösel, et al.Journal of Neural Transmission. Supplementum|January 1, 1995
Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's diseaseK Jellinger, L Linert, E Kienzl, et al.Pageof 68